Comparing two lab methods to measure leftover leukemia in acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two ways of analyzing blood test results (flow cytometry) to see how much leukemia remains after treatment. The goal is to find out if a computer-based analysis is as good as or better than the manual method, which could make results faster and more consistent.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of acute myeloid leukemia (AML), a type of blood cancer.
- You can be an adult (18 or older) or a child/young adult (up to age 20).
- Your care must be tracked at the Bordeaux hospital database or pediatric cancer records.
- You must have had a specific blood test (flow cytometry) done after your first two treatment rounds to check for leftover cancer cells.
- You must agree (or your family agrees) to let researchers use your medical data for this study.
- Your type of AML must not be one of three rarer subtypes (M3, M6, or M7).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new lab method to screen for acute myeloid leukemia (AML), including a rare subtype called acute promyelocytic leukemia. It may help doctors diagnose and classify AML more quickly and accurately.
This study compares a new technique using light to detect leftover leukemia cells (Raman spectroscopy) with the standard method (flow cytometry) in people with acute lymphoblastic leukemia (ALL).
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.